<DOC>
	<DOC>NCT00216229</DOC>
	<brief_summary>To compare the efficiency of protection against hepatitis-B virus by administration of the combined vaccine against hepatitis A and B using the schedule 0-1-12 months against the schedule 0-1-6 months. 1. To compare the seroconversion (&gt;= 1 IU/l) and seroprotection (&gt;= 10 IU/l) rate at month 6,7,12 and 13. 2. To compare the distribution of anti-HBs at these different moments.</brief_summary>
	<brief_title>Twinrix Alternative Schedule Study</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 years or older; a good physical condition as confirmed by history and physical examination at entry of the study; for female participants who could become pregnant in the course of the study a contraceptive programme is foreseen; all participants have provided written informed consent. Employees occupationally exposed to hepatitis B virus Other exclusion criteria listed for the vaccine (licensed vaccine): Each acute disease at the inclusion in the study; A history of hypersensibility to one of the components of the vaccine; Simultaneous participation in another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>combined hepatitis A and B vaccine</keyword>
	<keyword>hepatitis B virus</keyword>
	<keyword>immunity</keyword>
</DOC>